Literature DB >> 21372715

Role of aspirin desensitization in the management of chronic rhinosinusitis.

Habib Rizk1.   

Abstract

PURPOSE OF REVIEW: This review is set to revisit the pathogenesis of aspirin-exacerbated respiratory disease (AERD), the diagnostic method used, and finally the real impact of aspirin desensitization on chronic sinusitis with nasal polyposis (CRSwNP) in aspirin intolerant patients. RECENT
FINDINGS: In AERD, increased baseline production of cysteinyl-leukotriene (Cys-LT) is associated with upregulation of Cys-LT receptors on nasal inflammatory cells. This is further aggravated by inhibition of cyclooxygenase-1 by aspirin and other NSAIDs. New-found genetic markers need further study. Oral aspirin challenge is still the gold standard of diagnosis and can be safely conducted in a specialized outpatient clinic. Oral and endonasal aspirin desensitization show positive impact on CRSwNP course with decreased polyp recurrence, decreased number of hospitalizations, and decreased need for corticosteroids. Modulation of arachidonic acid metabolism and inhibition of intracellular biochemical pathways in key inflammatory cells involving anti-inflammatory cytokines interleukin (IL)-4 and IL-13 explain the clinical outcomes.
SUMMARY: Future studies should focus on establishing the lowest possible dose to maintain disease under check, allowing more widespread use of this underutilized and underrecognized treatment modality.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21372715     DOI: 10.1097/MOO.0b013e3283450102

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  11 in total

1.  Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?

Authors:  Ludger Klimek; Ralph Dollner; Oliver Pfaar; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2014-06       Impact factor: 4.806

2.  [Adaptive desensitization for acetylsalicylic acid hypersensitivity: A success story?].

Authors:  G Mühlmeier; R Hausch; H Maier
Journal:  HNO       Date:  2015-10       Impact factor: 1.284

3.  [Guideline for "rhinosinusitis"-long version : S2k guideline of the German College of General Practitioners and Family Physicians and the German Society for Oto-Rhino-Laryngology, Head and Neck Surgery].

Authors:  B A Stuck; A Beule; D Jobst; L Klimek; M Laudien; M Lell; T J Vogl; U Popert
Journal:  HNO       Date:  2018-01       Impact factor: 1.284

4.  [ASA-intolerance syndrome and persistent rhinosinusitis : Differential diagnosis and treatment].

Authors:  H Kirsche; L Klimek
Journal:  HNO       Date:  2015-05       Impact factor: 1.284

5.  Immunomodulatory treatments for aspirin exacerbated respiratory disease.

Authors:  Rachel G Moebus; Joseph K Han
Journal:  Am J Rhinol Allergy       Date:  2012 Mar-Apr       Impact factor: 2.467

6.  [Aspirin desensitization: therapy options in patients with aspirin-exacerbated respiratory disease].

Authors:  R Weber; A Trautmann; W Randerath; W Heppt; W Hosemann
Journal:  HNO       Date:  2012-04       Impact factor: 1.284

7.  Endoscopic sinus surgery improves aspirin treatment response in aspirin-exacerbated respiratory disease patients.

Authors:  Sharan J Shah; Waleed M Abuzeid; Anusha Ponduri; Teresa Pelletier; Zhen Ren; Taha Keskin; Gigia Roizen; David Rosenstreich; Denisa Ferastraoaru; Elina Jerschow
Journal:  Int Forum Allergy Rhinol       Date:  2019-09-30       Impact factor: 3.858

Review 8.  Drug allergy: causes and desensitization.

Authors:  Richard Warrington
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

9.  Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease.

Authors:  Negar Mortazavi; Hossein Esmaeilzadeh; Mohammad Abbasinazari; Delara Babaie; Soheila Alyasin; Hesamodin Nabavizadeh; Elmira Esmailzadeh
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

Review 10.  Samter's Triad: State of the Art.

Authors:  Sung-Dong Kim; Kyu-Sup Cho
Journal:  Clin Exp Otorhinolaryngol       Date:  2018-04-13       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.